Celltrion Healthcare

Remsima

Remsima

Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. It was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA) and the U.S. Food and Drug Administration(FDA).

• Product Name : Remsima® / U.S. Product Name : Inflectra®
• INN : Infliximab
• Indications : Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), Psoriasis(PsO)
• Protein Type : Monoclonal antibody (mAb)
• Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
• Drug Approval Status : Korea, USA, Europe, Canada, Japan, etc.